Latest Ratios: P/E Ratio -222.4x · EV/EBITDA N/A · ROE -128.5%. (2019–2026 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.6B | $3.0B | $8.4B | $44M | $300M | $450M | — | — | — |
| Enterprise Value | $2.6B | $3.0B | $8.4B | $41M | $299M | $445M | — | — | — |
| P/E Ratio → | -222.36 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 195.26 | 225.64 | 1733.65 | 5.32 | 25.01 | 26.36 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -128.5% | -128.5% | -54.8% | -42.6% | -40.4% | -113.5% | — | — | — |
| ROA | -114.2% | -114.2% | -50.5% | -40.9% | -38.3% | -80.9% | -315.3% | -214.5% | -160.7% |
| ROIC | -721.3% | -721.3% | -67.9% | -43.8% | -42.2% | -103.3% | — | -3803.4% | — |
| ROCE | -126.7% | -126.7% | -56.5% | -46.8% | -42.6% | -113.3% | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.11 | 0.01 | 0.04 | 0.05 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.04 | -0.39 | -0.35 | -0.09 | -0.33 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($14M) exceeds total debt ($295811)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.77 | 10.77 | 7.39 | 41.92 | 19.15 | 28.46 | 0.02 | 0.12 | 0.12 |
| Quick Ratio | 10.77 | 10.77 | 7.39 | 41.92 | 19.24 | 28.51 | 0.02 | 0.12 | 0.12 |
| Cash Ratio | 10.75 | 10.75 | 7.38 | 41.13 | 19.06 | 28.41 | 0.01 | 0.12 | 0.12 |
| Asset Turnover | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $495M | $494M | $494M | $494M | $494M | $480M | $480M | $480M |
Includes 30+ ratios · 8 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RGC stock.
Regencell Bioscience Holdings Limited's current P/E ratio is -222.4x. This places it at the 50th percentile of its historical range.
Regencell Bioscience Holdings Limited's return on equity (ROE) is -128.5%. The historical average is -76.0%.
Based on historical data, Regencell Bioscience Holdings Limited is trading at a P/E of -222.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Key Metrics
Top Statement Risk
Cash burn against thin revenue base
Earnings-Based Multiples Lack Meaning
Based on the reported figures, RGC's trailing P/E of -731.94 and P/B of 536.17 are not meaningful as value signals, since negative earnings and a minimal equity base distort conventional multiples relative to its own history and to peers such as NUVB at -6.93 P/E.
With net losses persisting and no forward P/E or EV/EBITDA available, the multiples cannot be anchored to earnings power. The P/B of 536.17 appears to reflect a small book value rather than premium pricing, which suggests investors may be valuing the company on prospective clinical or commercial milestones not visible in the reported data. Investors should monitor future earnings and cash flow before relying on any multiple-based valuation.
Debt Immaterial Against Thin Equity
According to recent SEC filings, RGC's debt-to-equity ratio of 0.02 at 2026Q4 indicates leverage is minimal, though total debt of $295.8K against $13.3M equity leaves solvency largely unconstrained by borrowing.
The low D/E ratio, relative to its own 2023Q4 level of 0.04 and 2025Q4 level of 0.11, suggests the company has been reducing reliance on debt as equity was rebuilt through capital raises. Interest coverage and D/EBITDA are unavailable because operating income is negative, so debt service capacity cannot be measured directly. The leverage picture therefore reflects limited borrowing rather than demonstrated earnings capacity to service obligations.
Cash Cushion Sized Against Burn
As reported in financial statements, RGC's current ratio of 10.77 and $14.2M cash at 2026Q4 appear robust, but they must be weighed against an operating cash outflow of -$5.1M in that same quarter.
Liquidity ratios are elevated relative to the 2025Q4 level of 7.39, indicating the cash position has strengthened through recent financing. However, at the current burn rate the cash balance implies a runway that investors should assess against planned spending. The high current ratio mainly reflects the cash-heavy asset base rather than operating strength, so stress scenarios depend on the pace of future outflows.
Returns Deeply Negative Across Periods
Based on reported figures, RGC's ROE of -70.1% and ROIC of -3.9% at 2026Q4 show returns remain negative, with the ROE deterioration from -29.9% in 2025Q4 pointing to losses growing faster than the equity base.
The negative ROE and ROA indicate the company is not generating returns on the capital invested by shareholders, and the lack of a consistent positive trend suggests no compounding is yet occurring. The divergence between ROE and ROIC in the latest period appears partly driven by the rebuilt equity base, so the ratios should be read with caution. Returns would need sustained operating profitability before they carry meaning for capital allocation.
Peer Gaps Reflect Stage, Not Scale
Compared with NUVB at -49.7% ROE and AEYE at -108.8% ROE, RGC's -70.1% ROE at 2026Q4 sits in the middle of the peer range, while its D/E of 0.02 is far below both peers' leverage.
RGC's low leverage distinguishes it from AEYE, whose D/E of 2.75 reflects a more indebted structure, and its return profile is not an outlier within this small peer set. The gaps appear largely structural, tied to early-stage operating economics rather than temporary margin pressure. Investors should note that the peer group is limited and that neither comparator is a close operating analogue.
Misapplied Current Ratio Overstates Safety
Based on reported figures, RGC's current ratio of 10.77 at 2026Q4 is the metric most likely to be misapplied here, since it treats a cash-heavy balance sheet as operating strength despite an operating cash outflow of -$5.1M in the same quarter.
For a pre-revenue, cash-burning biotech, the current ratio mainly reflects the size of a financing-funded cash balance rather than the ability to generate liquidity from operations. A more appropriate lens is months of cash runway, calculated as cash divided by average quarterly operating burn, which would convert the $14.2M cash balance into a timeline investors can compare against planned spending. This framing warrants further investigation, as the runway, not the ratio, determines how much time the balance sheet buys.